Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Return on Sales (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Return on Sales for 4 consecutive years, with 3.49% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 264.0% to 3.49% in Q3 2025 year-over-year; TTM through Sep 2025 was 2.17%, a 127.0% decrease, with the full-year FY2024 number at 0.97%, up 217.0% from a year prior.
  • Return on Sales was 3.49% for Q3 2025 at bioAffinity Technologies, down from 3.2% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.22% in Q2 2022 to a low of 4277.79% in Q3 2022.
  • A 4-year average of 483.18% and a median of 2.32% in 2025 define the central range for Return on Sales.
  • Biggest YoY gain for Return on Sales was 427011bps in 2023; the steepest drop was -8838bps in 2023.
  • bioAffinity Technologies' Return on Sales stood at 713.8% in 2022, then soared by 100bps to 1.07% in 2023, then decreased by -25bps to 1.34% in 2024, then plummeted by -160bps to 3.49% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Return on Sales are 3.49% (Q3 2025), 3.2% (Q2 2025), and 1.44% (Q1 2025).